Oncology Accelerated Approval Re-Reviews: US FDA’s Pazdur Is Not Backing Down

 
• By Michael McCaughan
  
Flipping calendar (Alamy)
ODAC may start having annual meetings about "dangling" accelerated approvals. • Source: Alamy

More from Review Pathways

More from Pathways & Standards